The incidence of allergic contact dermatitis from neomycin evaluated in relation to 1381 verified cases of allergic contact dermatitis showed a progressive increase (5.00, 7.69, 10.18%) over a three-year period (1990-1992). Sensitivity to neomycin was investigated with special reference to possible cross-reactions between neomycin and the allergens that are commonly used in the manufacture of cosmetic products. Contact sensitivity to neomycin was found to be present with the other diagnoses, such as atopic dermatitis, seborrhoeic dermatitis, hypostasic dermatitis and psoriasis vulgaris.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A Novel Technique for the Topical Application of Botulinum Neurotoxin A to the Nasal Mucosa in Reducing Rhinitis Symptoms.
Cureus
December 2024
Anatomy, Yonsei University, Seoul, KOR.
Introduction: To date, no investigations have been published regarding the concentration, dose, and technique for a mucosal spray application of botulinum toxin A (BTA) to alleviate hypersecretory symptoms of rhinitis in humans. It is a promising option for reducing common symptoms of seasonal allergic rhinitis (AR) and idiopathic non-AR. It is safer and less painful than intranasal injections, with high reported satisfaction in reducing clinical symptoms.
View Article and Find Full Text PDFA Case of Allergic Contact Dermatitis Due to Chrysanthemum After Guselkumab Therapy for Palmoplantar Pustulosis.
Cureus
December 2024
Department of Dermatology, Asahikawa Medical University, Asahikawa, JPN.
Eczematous paradoxical reactions are commonly associated with anti-interleukin-17A (anti-IL-17A) antibodies. However, IL-23 p19 inhibitors can also cause similar cutaneous manifestations. We present a case of a 77-year-old Japanese woman with palmoplantar pustulosis (PPP), who developed eczematous lesions on her face, neck, and dorsum of the hands 10 weeks after initiating guselkumab treatment.
View Article and Find Full Text PDFSulfites: The 2024 American Contact Dermatitis Society Allergen of the Year.
Cutis
November 2024
Solbie Choi is from the Albert Einstein College of Medicine, Bronx, New York. Sarak K. Zemlok is from the University of Connecticut School of Medicine, Farmington. Dr. Yu is from the Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston. Dr. Adler is from the Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles.
The American Contact Dermatitis Society (ACDS) selected sulfites as the 2024 Allergen of the Year. These common and potentially allergenic ingredients are used as preservatives and antioxidants in a variety of foods, beverages, medications, and personal care products. In this article, we review common sources of sulfite exposure, clinical manifestations of allergic contact dermatitis (ACD) to sulfites, and patch testing considerations for this emerging allergen.
View Article and Find Full Text PDFThe association between skin allergy testing and oral squamous cell carcinoma in oral lichen planus: a retrospective cohort study.
Arch Dermatol Res
January 2025
Department of Dermatology, Autoimmune Skin Diseases Clinic, University of Utah Spencer F. Eccles School of Medicine, 30 N Mario Capecchi Drive level 1 South, Salt Lake City, 84132, UT, USA.
There is a reported association between oral contact allergy and oral lichen planus (OLP). Likewise oral squamous cell carcinoma (oSCC) is associated with OLP. It is hypothesized that chronic inflammation may contribute to oSCC risk.
View Article and Find Full Text PDFEfficacy of 0.5% doxepin in coconut oil applied topically for chronic refractory pruritus: a case series from the VA Palo Alto Health Care System.
Arch Dermatol Res
January 2025
Department of Dermatology, Stanford University School of Medicine, 450 Broadway Street Pavilion B, 4th Floor, Redwood City, CA, 94063, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!